Respiratory Medicine Case Reports (Jan 2017)

EGFR or PD-L1 decision for first line therapy in a case series of EGFR positive and PD-L1 >50%

  • Paul Zarogoulidis,
  • Panos Chinelis,
  • Christofors Efthymiou,
  • Anastasia Athanasiadou,
  • Vasilis Mpikos,
  • George Papatsibas,
  • Vasilis Papadopoulos,
  • Elena Maragouli,
  • Haidong Huang,
  • Georgia Trakada,
  • Anastasios Kallianos,
  • Lemonia Veletza,
  • Wolfgang Hohenforst-Schmidt

DOI
https://doi.org/10.1016/j.rmcr.2017.05.010
Journal volume & issue
Vol. 22, no. C
pp. 7 – 10

Abstract

Read online

Targeted therapies are on the market for the past five years and recently pembrolizumab was approved as first line treatment for patients with PD-L1 >50%. We present three cases of patients which had epidermal growth factor receptor positive expression and programmed death-ligand 1 (PD-L1), PD-L1 >50% overexpression.

Keywords